These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37492354)

  • 41. [Treatment of blepharospasm, hemifacial spasm and facial synkinesis with botulinum toxin].
    Winterhoff J; Laskawi R
    HNO; 2012 Jun; 60(6):479-83. PubMed ID: 22669435
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Botulinum toxin for benign essential blepharospasm: A systematic review and an algorithmic approach.
    Rayess YA; Awaida CJ; Jabbour SF; Ballan AS; Sleilati FH; Abou Zeid SM; Nasr MW
    Rev Neurol (Paris); 2021; 177(1-2):107-114. PubMed ID: 32654779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
    Oliveira FC; Oliveira GC; Cariello AJ; Felberg S; Osaki MH
    Arq Bras Oftalmol; 2010; 73(5):405-8. PubMed ID: 21225122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
    Thussu A; Barman CR; Prabhakar S
    Neurol India; 1999 Sep; 47(3):206-9. PubMed ID: 10514580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years.
    Streitová H; Bareš M
    Acta Neurol Belg; 2014 Dec; 114(4):285-91. PubMed ID: 24604684
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A patient-initiated treatment model for blepharospasm and hemifacial spasm: a randomized controlled trial.
    Lawes-Wickwar S; McBain H; Brini S; Hirani SP; Hurt CS; Flood C; Dunlop N; Solly D; Crampton B; Newman SP; Ezra DG
    BMC Neurol; 2022 Mar; 22(1):99. PubMed ID: 35300599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study.
    Maneksha V; Chakrabarty S; Tanwar M; Pillai MR
    Indian J Ophthalmol; 2021 Oct; 69(10):2777-2781. PubMed ID: 34571634
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
    Yabiku MM; Sartori Jde F; Sarraff EP; Osaki TH; Hossaka SK; Pereira CI; Freitas Wd; Osaki MH; Cariello AJ
    Arq Bras Oftalmol; 2011; 74(6):414-6. PubMed ID: 22331113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term follow-up of patients with frontalis sling operation in the treatment of essential blepharospasm unresponsive to botulinum toxin therapy.
    Wabbels B; Roggenkämper P
    Graefes Arch Clin Exp Ophthalmol; 2007 Jan; 245(1):45-50. PubMed ID: 16874524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Demographic and clinical features of patients with blepharospasm in southern Taiwan: a university hospital-based study.
    Hwang WJ
    Acta Neurol Taiwan; 2012 Sep; 21(3):108-14. PubMed ID: 23196730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
    Shaw L; Rodgers H; Price C; van Wijck F; Shackley P; Steen N; Barnes M; Ford G; Graham L;
    Health Technol Assess; 2010 May; 14(26):1-113, iii-iv. PubMed ID: 20515600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
    Jost WH; Kohl A
    J Neurol; 2001 Apr; 248 Suppl 1():21-4. PubMed ID: 11357234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of hyperfunctional lines of the face with botulinum toxin A.
    Binder WJ; Blitzer A; Brin MF
    Dermatol Surg; 1998 Nov; 24(11):1198-205. PubMed ID: 9834739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Generalized botulism: diagnostic problems in a patient treated with botulinum toxin type A.
    Fota-Markowska H; Mitosek-Szewczyk K; Hasiec T
    Acta Ophthalmol Scand; 2007 Mar; 85(2):231-2. PubMed ID: 17305749
    [No Abstract]   [Full Text] [Related]  

  • 56. The long-term response to botulinum toxin injections in patients with blepharospasm undergoing upper eyelid surgery.
    Trinchillo A; Cuomo N; Habetswallner F; Esposito M
    Parkinsonism Relat Disord; 2024 Feb; 119():105958. PubMed ID: 38118281
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.
    Roggenkämper P; Jost WH; Bihari K; Comes G; Grafe S;
    J Neural Transm (Vienna); 2006 Mar; 113(3):303-12. PubMed ID: 15959841
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
    Sacramento DRC; Lima A; Maia DP; Cunningham M; Maciel RH; Camargos ST; Cardoso F
    Mov Disord; 2019 Sep; 34(9):1401-1403. PubMed ID: 31251420
    [No Abstract]   [Full Text] [Related]  

  • 59. Botulinum toxin and blink rate in patients with blepharospasm and increased blinking.
    Ferrazzano G; Conte A; Fabbrini G; Bologna M; Macerollo A; Defazio G; Hallett M; Berardelli A
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):336-40. PubMed ID: 24963123
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pain relief in patients receiving periocular botulinum toxin A.
    Harrison AR; Erickson JP; Anderson JS; Lee MS
    Ophthalmic Plast Reconstr Surg; 2008; 24(2):113-6. PubMed ID: 18356715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.